GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » PS Ratio

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) PS Ratio : 4.85 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 60 Degrees Pharmaceuticals's share price is $0.223. 60 Degrees Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Hence, 60 Degrees Pharmaceuticals's PS Ratio for today is 4.85.

Good Sign:

60 Degrees Pharmaceuticals Inc stock PS Ratio (=3.44) is close to 1-year low of 3.44

The historical rank and industry rank for 60 Degrees Pharmaceuticals's PS Ratio or its related term are showing as below:

SXTP' s PS Ratio Range Over the Past 10 Years
Min: 4.57   Med: 30   Max: 103.24
Current: 5.02

During the past 4 years, 60 Degrees Pharmaceuticals's highest PS Ratio was 103.24. The lowest was 4.57. And the median was 30.00.

SXTP's PS Ratio is ranked better than
68.9% of 1000 companies
in the Biotechnology industry
Industry Median: 9.125 vs SXTP: 5.02

60 Degrees Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05.

Warning Sign:

60 Degrees Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of 60 Degrees Pharmaceuticals was 60.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -45.30% per year.

During the past 4 years, 60 Degrees Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -45.30% per year. The lowest was -45.30% per year. And the median was -45.30% per year.

Back to Basics: PS Ratio


60 Degrees Pharmaceuticals PS Ratio Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals PS Ratio Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 15.94

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - 43.53 15.94

Competitive Comparison of 60 Degrees Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's PS Ratio falls into.



60 Degrees Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

60 Degrees Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.223/0.046
=4.85

60 Degrees Pharmaceuticals's Share Price of today is $0.223.
60 Degrees Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


60 Degrees Pharmaceuticals  (NAS:SXTP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


60 Degrees Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.
Executives
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines